SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal

SanegeneBio has entered a $1.5bn planetary licensing statement with Genentech, portion of the Roche Group, for 1 of its ribonucleic acerb interferences (RNAi) programmes utilising SanegeneBio’s exertion platform.

The woody grants Genentech exclusive planetary rights to make and commercialise the selected RNAi programme.

According to the contract, SanegeneBio volition negociate aboriginal improvement activities portion Genentech volition presume work for each consequent objective improvement and planetary commercialisation.

The collaboration centres connected SanegeneBio’s RNAi platform, which features caller chemistries and transportation technologies designed to make tiny interfering ribonucleic acerb (siRNA) medicines targeting aggregate illness areas.

The woody provides SanegeneBio with an upfront outgo of $200m. Additionally, the institution is eligible for improvement and commercialisation milestone payments that full up to $1.5bn, alongside tiered royalties based connected aboriginal merchandise sales.

SanegeneBio CEO and laminitis Weimin Wang said: “Entering into this statement with Genentech marks different important milestone for our innovative and differentiated RNAi chemistry and transportation platforms. We are delighted to enactment with a planetary technological person to proceed delivering effectual and life-changing therapies for patients worldwide.”

SanegeneBio operates arsenic a venture-backed biotechnology institution focused connected advancing RNAi-based therapeutics. The company’s probe and improvement (R&D) beingness spans Shanghai, Suzhou, and Boston.

Its improvement pipeline includes experimental medicines addressing cardiometabolic indications, obesity, and autoimmune nephropathies. The institution has already initiated objective trials for 4 experimental medicines targeting these areas, utilising its LEAD tissue-selective RNAi transportation technology.

In November 2025, SanegeneBio formed a worldwide probe and licensing concern with Eli Lilly and Company to make RNAi candidates for metabolic diseases.

"SanegeneBio and Genentech motion $1.5bn planetary RNAi licensing deal" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.